Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SACGHS Considers NCD, Inherent Reasonableness For Genetic Testing

This article was originally published in The Gray Sheet

Executive Summary

HHS Secretary Michael Leavitt should encourage CMS to address disparities between payment rates and actual costs of genetic tests, the Secretary's Advisory Committee on Genetics, Health & Society recommended Feb. 28

You may also be interested in...



Genetic test reimbursement

Public remarks concerning the HHS Secretary's Advisory Committee on Genetics, Health & Society's draft report on coverage and reimbursement of genetic tests and services are due May 6. In March, SACGHS recommended that HHS Secretary Michael Leavitt invoke "inherent reasonableness" authority, allowing an increase in payment rates for genetic tests (1"The Gray Sheet" March 7, 2005, p. 17)...

Genetic test reimbursement

Public remarks concerning the HHS Secretary's Advisory Committee on Genetics, Health & Society's draft report on coverage and reimbursement of genetic tests and services are due May 6. In March, SACGHS recommended that HHS Secretary Michael Leavitt invoke "inherent reasonableness" authority, allowing an increase in payment rates for genetic tests (1"The Gray Sheet" March 7, 2005, p. 17)...

Leavitt Nomination Will Enable MMA Implementation Continuity At CMS

President Bush's nomination of Michael Leavitt to head HHS will allow implementation of the Medicare Modernization Act to continue without distractions

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel